The Endocrine Society has officially launched its Center on Obesity, a comprehensive and multifaceted initiative designed to revolutionize the landscape of obesity care, research, and patient outcomes. Announced on September 9, 2024, the Center represents a strategic pivot for the Society, positioning it as a global leader in the fight against an epidemic that currently affects more than one billion people worldwide. The launch coincides with the publication of a landmark Scientific Statement in the journal Endocrine Reviews, which provides a rigorous evidence-based framework for the Center’s mission to move beyond simple weight loss toward a holistic model of "gaining health."
The establishment of the Center on Obesity comes at a pivotal moment in public health. Obesity is no longer viewed merely as a lifestyle condition but as a complex, chronic relapsing disease that serves as a gateway to nearly 200 other health complications, including type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and various forms of cancer. By consolidating its extensive resources, the Endocrine Society aims to provide a centralized hub for clinicians, researchers, and policymakers to collaborate on the next generation of obesity interventions.
A Scientific Mandate for Global Intervention
The launch of the Center on Obesity was synchronized with the release of the Society’s latest Scientific Statement, a document that underscores the biological complexities of weight regulation. This statement serves as the intellectual cornerstone of the Center, emphasizing that obesity is driven by sophisticated hormonal and neurological pathways rather than simple caloric imbalances.
According to Amy E. Rothberg, MD, a clinical professor of medicine at the University of Michigan and chair of the Society’s Obesity Task Force, the decision to prioritize this initiative was driven by the unique expertise of the Society’s membership. For more than two decades, endocrinologists have been at the forefront of identifying the hormonal drivers of appetite and metabolism. Dr. Rothberg, who also serves as the director of the Obesity Medicine Fellowship at the University of Michigan, noted during a virtual news conference that the Center is the culmination of years of advocacy and clinical progress.
The Society’s history in this field is extensive. It played a critical role in successfully lobbying the American Medical Association (AMA) to recognize obesity as a disease in 2013—a move that fundamentally changed how the medical community and insurance providers approach the condition. Furthermore, the Society has been a consistent advocate for the Treat and Reduce Obesity Act (TROA), a piece of legislation aimed at expanding Medicare coverage for intensive behavioral therapy and FDA-approved anti-obesity medications.
The Evolution of Obesity Pharmacotherapy
One of the primary drivers behind the Center’s launch is the rapid evolution of pharmacological treatments, most notably the emergence of Glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, originally developed to treat diabetes, have demonstrated unprecedented efficacy in weight reduction, with newer "triple agonist" therapies like retatrutide showing the potential for weight loss exceeding 30% of total body weight.
However, the "blockbuster" status of these drugs has brought new challenges. Many patients experience significant side effects, including gastrointestinal distress, nausea, and the loss of lean muscle mass. Additionally, issues of cost, insurance coverage, and long-term accessibility have created barriers for many of those who need treatment most.
M. Furkan Burak, MD, an instructor in medicine at Brigham and Women’s Hospital and Harvard Medical School, emphasized that the Center on Obesity will play a vital role in navigating these complexities. Dr. Burak, who serves as an associate editor of the Journal of the Endocrine Society, explained that the next era of obesity medicine will be defined by "precision medicine." His research team’s work on asthma led to a breakthrough understanding of adipose tissue (fat) as an active endocrine organ. When adipose tissue becomes dysfunctional, it triggers a systemic stress response that contributes to metabolic collapse.
By understanding the specific neural circuits that drive satiety versus those that cause nausea, researchers are now developing more "tolerable" medications. The Center on Obesity will facilitate the dissemination of this research, ensuring that clinicians can tailor treatments to the specific physiological makeup of individual patients.
Chronology of Advocacy and Innovation
The formation of the Center on Obesity is the result of a multi-decade timeline of scientific and legislative milestones:
- 2005: The first GLP-1 receptor agonists are introduced to clinical practice, primarily for the management of type 2 diabetes.
- 2013: The American Medical Association officially recognizes obesity as a disease, following intensive advocacy by the Endocrine Society and its partners.
- 2015-2020: Research accelerates into the "brain-gut axis," identifying how hormones like ghrelin, leptin, and GLP-1 communicate with the central nervous system to regulate energy balance.
- 2021-2023: The emergence of highly potent dual and triple agonists (such as tirzepatide and retatrutide) shifts the conversation from modest weight loss to results comparable to bariatric surgery.
- September 9, 2024: The Endocrine Society launches the Center on Obesity to unify research, clinical practice, and policy under a single institutional roof.
Supporting Data and the Economic Burden of Obesity
The urgency behind the Center’s mission is supported by staggering global health data. The World Health Organization (WHO) reports that obesity rates have nearly tripled since 1975. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that more than 42% of adults are currently living with obesity, with medical costs for these individuals being approximately $1,861 higher per year than those at a healthy weight.
The economic implications are equally profound. Global estimates suggest that the economic impact of obesity could reach $4.32 trillion annually by 2035 if current trends continue. This includes not only direct healthcare costs but also lost productivity and the management of associated chronic conditions. By focusing on "health gain"—the preservation of muscle mass, bone density, and immune function—the Center on Obesity aims to mitigate these long-term societal costs.
Official Responses and Clinical Implications
The medical community has responded to the Center’s launch with significant optimism. Dr. Burak noted that for years, obesity medicine has been a "fractured field," split between various local and international associations with differing priorities. The Endocrine Society, as a global leader in hormone science, provides a stabilizing influence.
"The Endocrine Society is the leading organization for hormone science globally, so it’s really helped to bring together the other associations and small communities into the action," Burak stated. He believes that by housing research, clinical practice, policy, and education under one roof, the Society can ensure that the "endocrine community’s voice shapes where obesity medicine goes next."
For clinicians, the Center offers a repository of resources to help patients who have historically been reluctant to seek care due to the stigma associated with weight. Dr. Rothberg expressed hope that the empowerment of patients, combined with a robust pipeline of combination therapies, will lead to a new standard of care where the patient’s quality of life is the primary metric of success.
Broader Impact and Future Outlook
Looking ahead, the Center on Obesity is expected to influence several key areas of medicine and society. First, it will likely drive the development of new clinical guidelines that incorporate precision medicine, helping doctors identify which patients will respond best to specific drug classes. Second, it will provide a stronger platform for legislative advocacy, pushing for broader insurance coverage of anti-obesity medications and behavioral interventions.
The Center also aims to address the "muscle loss" concern associated with rapid weight loss. By focusing on the protection of bone and muscle health, the initiative seeks to ensure that weight loss does not come at the expense of physical strength or metabolic rate. This holistic approach marks a departure from the "weight-centric" models of the past, focusing instead on "metabolic health."
As the Endocrine Society moves forward with this initiative, the Center on Obesity stands as a testament to the power of integrating laboratory science with clinical advocacy. By providing a "home" for the latest developments in the field, the Society ensures that the future of obesity medicine is not just about the numbers on a scale, but about the long-term health and vitality of a global population. The transition from "weight loss" to "health gain" represents a fundamental shift in the medical paradigm, one that the Endocrine Society is now uniquely positioned to lead.
